UBS raised the firm’s price target on Pfizer (PFE) to $27 from $25 and keeps a Neutral rating on the shares. The firm adjusted targets in the pharmaceuticals and biotechnology group as part of a Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE: